Boston Scientific Corporation

As of June 30, 2026, Boston Scientific Corporation carries a market capitalization of 1.10T, placing it among publicly traded companies globally. Its enterprise value stands at 1.31T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Boston Scientific Corporation's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Boston Scientific Corporation has 1.45B shares outstanding.

As of June 30, 2026, Boston Scientific Corporation trades at a trailing price-to-earnings ratio of 17.49. The price-to-sales ratio is 3.06, and the price-to-book ratio stands at 2.52.

As of June 30, 2026, Boston Scientific Corporation trades at an EV/EBITDA multiple of 13.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.10 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Boston Scientific Corporation trades at an EV/FCF ratio of 19.37, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.31T versus a market cap of 1.10T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Boston Scientific Corporation maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.15, indicating elevated leverage, while an interest coverage ratio of 15.33 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Boston Scientific Corporation posted a return on equity (ROE) of 15.52, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.11, useful for judging operating efficiency across full business cycles. The company generates approximately 6.38M in revenue per employee across its workforce of 57,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.07 indicates how many times Boston Scientific Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Boston Scientific Corporation recorded 3.35B in income tax expense. That works out to an effective tax rate of 4.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 67.46B, leaving 64.21B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Boston Scientific Corporation's stock has declined approximately 55.30% over the past 52 weeks. The 50-day moving average sits at 802.55, while the 200-day moving average is 1,156.81.

Over the twelve months ended June 30, 2026, Boston Scientific Corporation generated 366.83B in revenue and converted that into 64.21B in net income, yielding earnings per share of 43.01. EBITDA reached 97.23B, while operating income came in at 77.03B.

As of June 30, 2026, Boston Scientific Corporation holds 9.42B in cash and equivalents against 220.56B in total debt, resulting in a net debt position of 208.98B. Total book value stands at 435.57B, with working capital of 26.98B providing operational flexibility.

Boston Scientific Corporation produced 79.13B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -17.35B in capital expenditures, free cash flow totaled 61.78B - equivalent to 41.75 per share.

Over the twelve months ended June 30, 2026, Boston Scientific Corporation posted a gross margin of 69.92, reflecting its pricing power and cost economics. The operating margin of 21.00 and net profit margin of 17.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 5.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Boston Scientific Corporation shareholders.

Boston Scientific Corporation's most recent stock split took place on November 6, 2003 with a 1:2 split ratio.

As of June 30, 2026, Boston Scientific Corporation has an Altman Z-Score of 4.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.